Entellus Medical

Investor Relations

We are a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of patients in the physician office setting or operating room who are suffering from chronic sinusitis. Our XprESS family of products is used by ear, nose and throat, or ENT, physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation to treat patients with symptomatic inflammation of the nasal sinuses.
Stock Information
ENTL (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) - 0.16 (0.83%)
Data as of 12/08/16 4:00 p.m. ET
Minimum 15 minute delay
Refresh quote
Stock chart for: ENTL.O.  Currently trading at $19.17 with a 52 week high of $22.63 and a 52 week low of $13.72.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Recent NewsMore >>
11/29/16Entellus Medical Announces Publication of Positive Clinical Data for XprESS for Treatment of Pediatric Chronic Rhinosinusitis
11/16/16Entellus Medical to Present at the Piper Jaffray Healthcare Conference
11/03/16Entellus Medical Announces Third Quarter 2016 Financial Results
10/24/16Entellus Medical to Report Third Quarter 2016 Financial Results on November 3, 2016
Upcoming EventsMore >>
There are currently no events scheduled.